Ulrich Freudensprung

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Ludwig Kappos, Hans‐Peter Hartung, Mark S. Freedman et al. · The Lancet Neurology · 2014 · 330 citations

Life Sciences, Neurology, Neuroimmunology +4

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

Martin R. Stockler, Felix Hilpert, Michael Friedländer et al. · Journal of Clinical Oncology · 2014 · 175 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

Gϋnter von Minckwitz, Fabio Puglisi, Javier Cortés et al. · The Lancet Oncology · 2014 · 146 citations

Medicine, Oncology, Pharmacotherapy +17

Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Joseph Gligorov, Dinesh Doval, José Bines et al. · The Lancet Oncology · 2014 · 127 citations

Medicine, Oncology, Pharmacotherapy +17

ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis

Robert C. Sergott, Jeffrey L. Bennett, Xavier Montalbán et al. · Journal of the Neurological Sciences · 2015 · 81 citations

Medicine, Neurology, Ophthalmology +16